Devonian Health Group Inc. (TSXV:GSD)

Canada flag Canada · Delayed Price · Currency is CAD
13.75
+1.50 (12.24%)
At close: Feb 27, 2026
Market Cap38.03M +31.6%
Revenue (ttm)18.52M -23.0%
Net Income-6.97M
EPS-2.74
Shares Out2.77M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,000
Average Volume1,589
Open13.70
Previous Close12.25
Day's Range13.70 - 13.75
52-Week Range5.10 - 15.00
Beta1.40
RSI57.66
Earnings DateMar 27, 2026

About Devonian Health Group

Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops Pantoprazole Magnesium for the treatm... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Andre Boulet
Employees 11
Stock Exchange TSX Venture Exchange
Ticker Symbol GSD
Full Company Profile

Financial Performance

In fiscal year 2025, Devonian Health Group's revenue was 23.59 million, an increase of 22.19% compared to the previous year's 19.31 million. Losses were -6.01 million, 229.1% more than in 2024.

Financial Statements